Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL.

MLA

Hartert, Keenan T., et al. “Targeting of Inflammatory Pathways with R2CHOP in High-Risk DLBCL.” Leukemia, vol. 35, no. 2, Feb. 2021, pp. 522–33. EBSCOhost, https://doi.org/10.1038/s41375-020-0766-4.

APA

Hartert, K. T., Wenzl, K., Krull, J. E., Manske, M., Sarangi, V., Asmann, Y., Larson, M. C., Maurer, M. J., Slager, S., Macon, W. R., King, R. L., Feldman, A. L., Gandhi, A. K., Link, B. K., Habermann, T. M., Yang, Z.-Z., Ansell, S. M., Cerhan, J. R., Witzig, T. E., … Novak, A. J. (2021). Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. Leukemia, 35(2), 522–533. https://doi.org/10.1038/s41375-020-0766-4

Chicago

Hartert, Keenan T, Kerstin Wenzl, Jordan E Krull, Michelle Manske, Vivekananda Sarangi, Yan Asmann, Melissa C Larson, et al. 2021. “Targeting of Inflammatory Pathways with R2CHOP in High-Risk DLBCL.” Leukemia 35 (2): 522–33. doi:10.1038/s41375-020-0766-4.